These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 16919303

  • 41. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs.
    Turrel JM, Kitchell BE, Miller LM, Théon A.
    J Am Vet Med Assoc; 1988 Oct 15; 193(8):936-40. PubMed ID: 3142828
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. What is your diagnosis? Mast cell sarcoma.
    Dunn K.
    J Small Anim Pract; 1997 Mar 15; 38(3):93, 108. PubMed ID: 9097238
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y, Perdreau SA, Chatterjee P, Wang L, Kuan SF, Duensing A.
    Cancer Res; 2008 Nov 01; 68(21):9015-23. PubMed ID: 18974147
    [Abstract] [Full Text] [Related]

  • 51. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
    Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL.
    Vet Comp Oncol; 2010 Sep 01; 8(3):209-20. PubMed ID: 20691028
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Debate on grade-III mast cell tumors continues.
    Koltveit AJ.
    J Am Vet Med Assoc; 2004 Apr 01; 224(7):1071. PubMed ID: 15074849
    [No Abstract] [Full Text] [Related]

  • 55. Questions data supporting conclusions on grade-III mast cell tumors.
    Schulman FY, Lipscomb TP.
    J Am Vet Med Assoc; 2004 Feb 15; 224(4):501; author reply 501. PubMed ID: 14989538
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Morphometry of canine cutaneous mast cell tumors.
    Strefezzi Rde F, Xavier JG, Catão-Dias JL.
    Vet Pathol; 2003 May 15; 40(3):268-75. PubMed ID: 12724567
    [Abstract] [Full Text] [Related]

  • 58. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 59. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
    Benny O, Menon LG, Ariel G, Goren E, Kim SK, Stewman C, Black PM, Carroll RS, Machluf M.
    Clin Cancer Res; 2009 Feb 15; 15(4):1222-31. PubMed ID: 19190128
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.